Published in Blood Weekly, December 18th, 2003
According to published research from the United States, "Although U.S. immune globulin intravenous (human) (IGIV) products have been regarded as safe, it is important to recognize that many of the controlled clinical studies of IGIVs have been of modest size and have limited power to define the incidence of only the most common adverse events (AEs). A significant number of 'postmarketing' serious AEs affecting renal, cardiovascular, CNS, integumentary, and hematologic organ systems have been reported."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.